Study findings suggested that assessing ctDNA levels was as good or better at predicting recurrence than experimental tests ...

Monitoring circulating tumor DNA levels before and during treatment may predict melanoma recurrence, offering a potential ...

Researchers showed that approximately 80 percent of stage 3 melanoma patients who had detectable levels of circulating tumor ...

Droplet digital polymerase chain reaction (PCR) measurements of cell-free, circulating tumor DNA (ctDNA) can identify ...

Monitoring blood levels of DNA fragments shed by dying tumor cells may accurately predict skin cancer recurrence, a new study ...

DNA fragments found in the bloodstream during treatment could mean that a patient’s cancer is getting worse, researchers said ...

CURE spoke with Dr. Michael K. Wong and Dr. Diwakar Davar about the use of ctDNA for patients with melanoma, and where the ...

Monitoring blood levels of DNA fragments shed by dying tumor cells may accurately predict skin cancer recurrence, a new study shows.